Navigation Links
Bionovo Announces 2009 Highlights and Year-End Financial Results
Date:3/15/2010

As of December 31, 2009, cash, cash equivalents and short-term investments totaled approximately $15.9 million compared to $13.6 million at December 31, 2008. The increase is due to the public offering completed in October of 2009 resulting in net proceeds of $17.4 million, partially offset by cash used in operating activities. The net cash used in operating activities for 2009 was $13.3 million, compared with $15.3 million in 2008.

2010 Expense and Cash Guidance

Operating expenses in 2010 are expected to follow a run-rate of $1.0-1.5 million per month. Operating expenses will increase from the current run rate of $1.0 million per month when clinical trial activities increase.

The Company currently has enough funds to continue operating through 2010 into the first quarter of 2011. The Company will need to seek additional funding prior to that time, in order to continue operations and/or to increase the clinical testing program and other research.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
2. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
3. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
4. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
5. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
6. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
7. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
9. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
10. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 According to Kalorama ... needed to make Big Data in healthcare a reality, ... As part of the American Recovery and Reinvestment Act, ... record (EMR) projects and penalties will start applying soon ... Information, in its complete study of the EMR industry, ...
(Date:8/19/2014)...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management ... and Regeneron will host an IR Thematic Conference Call on Alirocumab ... 2014 , Baird 2014 Healthcare Conference at 4:05 ... , Citi,s 9 th Annual Biotech Conference at ... , Morgan Stanley Global Healthcare Conference at 8:45 ...
(Date:8/19/2014)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" "the company") announced today a protocol amendment to ... been filed with the U.S. Food and Drug Administration (FDA) ... has been opened at three clinical trial sites in ... confirmed that gross proceeds of US$2.9 million have been raised ...
Breaking Medicine Technology:Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7
... Oct. 6 Complete,Genomics Inc., a newly launched, ... Systems Biology (ISB) today announced their,partnership to conduct ... of the project, Complete Genomics will use its ... samples provided by,ISB. Then, once proof-of-concept has been ...
... will host a conference call today, Monday, October ... to review the outcome of the interim analysis ... known as D9902B),clinical trial of PROVENGE(R) (sipuleucel-T), the ... advanced prostate,cancer., Those interested may ...
Cached Medicine Technology:Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 This ... line of software defined networking, high availability cloud ... portfolio of Resellers, while allowing OPEN-V to sell ... is pleased to work with OPEN-V on this ... Donald Hows, manager distribution channels at storageFOUNDRY. "Nautilus ...
(Date:8/19/2014)... BambooIndustry.com, a well-known bamboo product manufacturer and retailer, ... recently. The company is excited to reveal the new items, ... for all clients. Now, every customer can get a discounted ... until August 30. , The company’s deckings are made ... for supreme durability. They are perfect for a dining room, ...
(Date:8/19/2014)... Crosley Law Firm, PC has reached a confidential ... Star Bakery for an undisclosed amount. The two claimants, Pete ... of 2011, respectively. The injuries were caused by two different ... to the left hand of each man. , At the ... short-staffed, having lost 200 of its, 500 workers in connection ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, Skmen.com, an ... assortment of 2014 bohemian dresses . In addition to ... these elegant items. Now, all of them are available at ... puts emphasis on product design and quality. Its beautiful bohemian ... purple, blue and many others. Owing to its top quality ...
(Date:8/19/2014)... involved in multitasking and ways to train it have ... Institut universitaire de griatrie de Montral and the University ... predict the effectiveness of this training. Cooking while having ... or driving while listening to a radio show ... lives. Unfortunately, it decreases with age, which makes it ...
Breaking Medicine News(10 mins):Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Promotional Bamboo Deckings from Well-known Online Supplier BambooIndustry.com 2Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Targeted brain training may help you multitask better 2
... NEW YORK, Aug. 11 Healthcare reform has become a hot button ... one organization,s attempts to clear the air and separate fact from fiction. ... http://inr.mediaseed.tv/oneClip_C/?feed=_QhsLVZADdDFnJstv e QtY97yVQFUg6so , ... and photos for free and unrestricted use at http://www.medi ...
... counters effects of hormone therapy, study finds , TUESDAY, ... has worked well in a trial of men whose ... taking for prostate cancer, researchers report. , The drug, ... hopes to market for fracture prevention, not only in ...
... PHILADELPHIA A new study conducted at the ... in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy ... phase three FREEDOM-301 trial for the orally-inhaled migraine ... from symptoms such as pain, nausea and light ...
... team approach to preventive healthcare delivery for older adults ... Institute improves health and quality of life, decreased emergency ... second year the new model saved money for the ... in the third year, a year after the home-based ...
... , , , ... 11 Masimo (Nasdaq: MASI ), the ... pulse oximetry, and Oridion (SIX Swiss Exchange: ORIDN), a ... an agreement to establish compatibility and connectivity between Oridion ...
... Fla., Aug. 11 Jeff Korte, former Major with the Florida Division ... Investigative Unit (SIU) for Litigation Solutions, LLC. , ... enforcement experience to Litigation Solutions, spending the past 20 years with the ... in 2008. , , During his tenure ...
Cached Medicine News:Health News:New Bone-Building Drug Promising Against Prostate Cancer 2Health News:New Bone-Building Drug Promising Against Prostate Cancer 3Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 2Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 3Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 2Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 3Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 4Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 5Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 6Health News:Jeff Korte Named as SIU Director, Litigation Solutions, LLC 2
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Size 4 - 2.25 mm...
The Storz Protege is an anterior segment unit only....
Medicine Products: